{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:06:01Z","timestamp":1769839561598,"version":"3.49.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T00:00:00Z","timestamp":1331683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11940-012-0169-6","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T08:12:50Z","timestamp":1331626370000},"page":"213-229","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of Focal Dystonia"],"prefix":"10.1007","volume":"14","author":[{"given":"Amit","family":"Batla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stamelou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailash P.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,14]]},"reference":[{"key":"169_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.50.5_Suppl_5.S1","volume":"78","author":"S Fahn","year":"1998","unstructured":"Fahn S, Bressman S, Marsden CD. Classification of dystonia. Adv Neurol. 1998;78:1\u201310.","journal-title":"Adv Neurol"},{"key":"169_CR2","first-page":"321","volume-title":"Parkinson\u2019s disease and movement disorders","author":"J Jankovic","year":"2007","unstructured":"Jankovic J. Dystonic disorders. In: Tolosa JJ, editor. Parkinson\u2019s disease and movement disorders. 5th ed. Philadelphia: Williams and Wilkins; 2007. p. 321\u201347.","edition":"5"},{"key":"169_CR3","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1474-4422(06)70574-9","volume":"5","author":"J Jankovic","year":"2006","unstructured":"Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5:864\u201372.","journal-title":"Lancet Neurol"},{"key":"169_CR4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.biochem.051908.125345","volume":"79","author":"M Montal","year":"2010","unstructured":"Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem. 2010;79:591\u2013617.","journal-title":"Annu Rev Biochem"},{"issue":"19","key":"169_CR5","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A, Comella C, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699\u2013706.","journal-title":"Neurology"},{"issue":"1","key":"169_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","volume":"18","author":"A Albanese","year":"2011","unstructured":"Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5\u201318","journal-title":"Eur J Neurol"},{"issue":"5","key":"169_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1468-1331.2006.01537.x","volume":"13","author":"A Albanese","year":"2006","unstructured":"Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS\/MDS-ES Task Force. Eur J Neurol. 2006;13(5):433\u201344.","journal-title":"Eur J Neurol"},{"key":"169_CR8","first-page":"CD003633","volume":"1","author":"J Costa","year":"2005","unstructured":"Costa J, Esp\u00edrito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD003633.","journal-title":"Cochrane Database Syst Rev."},{"key":"169_CR9","first-page":"CD004312","volume":"1","author":"J Costa","year":"2005","unstructured":"Costa J, Esp\u00edrito-Santo C, Borges A, et al. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD004312.","journal-title":"Cochrane Database Syst Rev."},{"key":"169_CR10","first-page":"CD004315","volume":"1","author":"J Costa","year":"2005","unstructured":"Costa J, Esp\u00edrito-Santo C, Borges A, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD004315.","journal-title":"Cochrane Database Syst Rev."},{"key":"169_CR11","first-page":"CD004314","volume":"1","author":"J Costa","year":"2005","unstructured":"Costa J, Borges A, Esp\u00edrito-Santo C, Ferreira J, et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD004314.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"169_CR12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","volume":"49","author":"MF Lew","year":"1997","unstructured":"Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49(3):701\u20137.","journal-title":"Neurology"},{"issue":"7","key":"169_CR13","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","volume":"53","author":"A Brashear","year":"1999","unstructured":"Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439\u201346.","journal-title":"Neurology"},{"issue":"7","key":"169_CR14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","volume":"53","author":"MF Brin","year":"1999","unstructured":"Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431\u20138.","journal-title":"Neurology"},{"issue":"9","key":"169_CR15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","volume":"65","author":"CL Comella","year":"2005","unstructured":"Comella CL, Jankovic J, Shannon KM, Dystonia Study Group, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65(9):1423\u20139.","journal-title":"Neurology"},{"issue":"4","key":"169_CR16","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","volume":"23","author":"EJ Pappert","year":"2008","unstructured":"Pappert EJ, Germanson T, Myobloc\/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-na\u00efve patients with cervical dystonia: Randomized, double-blind, non inferiority trial. Mov Disord. 2008;23(4):510\u20137.","journal-title":"Mov Disord"},{"issue":"1","key":"169_CR17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00839206","volume":"239","author":"W Poewe","year":"1992","unstructured":"Poewe W, Schelosky L, Kleedorfer B, et al. Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients. J Neurol. 1992;239(1):21\u20135.","journal-title":"J Neurol"},{"issue":"7","key":"169_CR18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","volume":"20","author":"D Truong","year":"2005","unstructured":"Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20(7):783\u201391.","journal-title":"Mov Disord"},{"issue":"11","key":"169_CR19","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","volume":"64","author":"R Benecke","year":"2005","unstructured":"Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949\u201351.","journal-title":"Neurology"},{"issue":"4","key":"169_CR20","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","volume":"46","author":"JW Brans","year":"1996","unstructured":"Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996;46(4):1066\u201372.","journal-title":"Neurology"},{"key":"169_CR21","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.40.8.1213","volume":"40","author":"P Greene","year":"1990","unstructured":"Greene P, Kang U, Fahn S, et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990;40:1213\u20138.","journal-title":"Neurology"},{"issue":"8","key":"169_CR22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.20468","volume":"20","author":"A Marchetti","year":"2005","unstructured":"Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord. 2005;20(8):937\u201344.","journal-title":"Mov Disord"},{"issue":"1","key":"169_CR23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","volume":"64","author":"T Odergren","year":"1998","unstructured":"Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64(1):6\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"169_CR24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/med\/9780198569848.001.0001","volume-title":"Oxford specialist handbook: Parkinson\u2019s disease and other movement disorders","author":"M Edwards","year":"2008","unstructured":"Edwards M, Quinn N, Bhatia K. Dystonia. In: Edwards M, Quinn N, Bhatia K, editors. Oxford specialist handbook: Parkinson\u2019s disease and other movement disorders. Oxford: Oxford University Press; 2008. p. 202\u20137."},{"key":"169_CR25","unstructured":"Allergan. BOTOX\u00ae Prescribing Information [online]. Available at: http:\/\/www.allergan.com\/assets\/pdf\/botox_pi.pdf"},{"issue":"9","key":"169_CR26","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1007\/s00415-011-5998-9","volume":"258","author":"P Burbaud","year":"2011","unstructured":"Burbaud P, Ducerf C, Cugy E, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258(9):1670\u20135.","journal-title":"J Neurol"},{"issue":"4","key":"169_CR27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-007-0831-4","volume":"115","author":"CL Comella","year":"2008","unstructured":"Comella CL. The treatment of cervical dystonia with botulinum toxins. J Neural Transm. 2008;115(4):579\u201383.","journal-title":"J Neural Transm."},{"issue":"7","key":"169_CR28","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.41.7.1088","volume":"41","author":"J Jankovic","year":"1991","unstructured":"Jankovic J, Leder S, Warner D, et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991;41(7):1088\u201391.","journal-title":"Neurology"},{"issue":"7","key":"169_CR29","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60(7):1186\u20138.","journal-title":"Neurology"},{"issue":"6","key":"169_CR30","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.asj.2009.09.009","volume":"29","author":"I Lawrence","year":"2009","unstructured":"Lawrence I, Moy R. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A. Aesthet Surg J. 2009;29(6):S66\u201371.","journal-title":"Aesthet Surg J."},{"key":"169_CR31","doi-asserted-by":"crossref","unstructured":"Skogseid IM, Ramm-Pettersen J, Volkmann J, et al. Good long-term efficacy of pallidal stimulation in cervical dystonia: a prospective, observer-blinded study. Eur J Neurol. 2011. doi: 10.1111\/j.1468-1331.2011.03591.x .This is a recent study assessing long-term efficacy of DBS in CD in a blinded form.","DOI":"10.1111\/j.1468-1331.2011.03591.x"},{"issue":"11","key":"169_CR32","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/brain\/awm229","volume":"130","author":"ZH Kiss","year":"2007","unstructured":"Kiss ZH, Doig-Beyaert K, Eliasziw M, et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Functional and Stereotactic Section of the Canadian Neurosurgical Society; Canadian Movement Disorders Group. Brain. 2007;130(11):2879\u201386.","journal-title":"Brain"},{"issue":"3","key":"169_CR33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3171\/JNS\/2008\/109\/9\/0405","volume":"109","author":"TE Pretto","year":"2008","unstructured":"Pretto TE, Dalvi A, Kang UJ, et al. A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg. 2008;109(3):405\u20139.","journal-title":"J Neurosurg"},{"issue":"6","key":"169_CR34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/01.wnl.0000252932.71306.89","volume":"68","author":"SW Hung","year":"2007","unstructured":"Hung SW, Hamani C, Lozano AM, et al. Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology. 2007;68(6):457\u20139.","journal-title":"Neurology"},{"issue":"4","key":"169_CR35","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1227\/NEU.0b013e3181ec49c7","volume":"67","author":"F Cacciola","year":"2010","unstructured":"Cacciola F, Farah JO, Eldridge PR, et al. Bilateral deep brain stimulation for cervical dystonia: long-term outcome in a series of 10 patients. Neurosurgery. 2010;67(4):957\u201363.","journal-title":"Neurosurgery"},{"issue":"1","key":"169_CR36","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1002\/mds.23535","volume":"26","author":"M Tagliati","year":"2011","unstructured":"Tagliati M, Krack P, Volkmann J, et al. Long-term management of DBS in dystonia: response to stimulation, adverse events, battery changes, and special considerations. Mov Disord. 2011;26(1):S54\u201362.","journal-title":"Mov Disord"},{"issue":"4","key":"169_CR37","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3340\/jkns.2009.46.4.346","volume":"46","author":"SG Jeong","year":"2009","unstructured":"Jeong SG, Lee MK, Kang JY, et al. Pallidal deep brain stimulation in primary cervical dystonia with phasic type: clinical outcome and postoperative course. J Korean Neurosurg Soc. 2009;46(4):346\u201350.","journal-title":"J Korean Neurosurg Soc."},{"issue":"3","key":"169_CR38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1525-1403.2005.05233.x","volume":"8","author":"J Yianni","year":"2005","unstructured":"Yianni J, Green AL, McIntosh E, et al. The costs and benefits of deep brain stimulation surgery for patients with dystonia: an initial exploration. Neuromodulation. 2005;8(3):155\u201361.","journal-title":"Neuromodulation"},{"issue":"2","key":"169_CR39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0090-3019(93)90118-K","volume":"40","author":"CM Bertrand","year":"1993","unstructured":"Bertrand CM. Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases. Surg Neurol. 1993;40(2):96\u2013103.","journal-title":"Surg Neurol"},{"issue":"2\u20133","key":"169_CR40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000048389","volume":"75","author":"X Chen","year":"2000","unstructured":"Chen X, Ma A, Liang J, et al. Selective denervation and resection of cervical muscles in the treatment of spasmodic torticollis: long-term follow-up results in 207 cases. Stereotact Funct Neurosurg. 2000;75(2\u20133):96\u2013102.","journal-title":"Stereotact Funct Neurosurg"},{"issue":"4","key":"169_CR41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/brain\/124.4.769","volume":"124","author":"A M\u00fcnchau","year":"2001","unstructured":"M\u00fcnchau A, Palmer JD, Dressler D, et al. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain. 2001;124(4):769\u201383.","journal-title":"Brain"},{"key":"169_CR42","unstructured":"National Institute for Clinical Excellence. Interventional Procedure Consultation Document Selective peripheral denervation for cervical dystonia www.nice.org.uk\/nicemedia\/pdf\/ip\/IPG080guidance.pdf ."},{"key":"169_CR43","first-page":"189","volume":"37","author":"RE Burke","year":"1983","unstructured":"Burke RE, Fahn S. Double-blind evaluation of trihexyphenidyl in dystonia. Adv Neurol. 1983;37:189\u201392.","journal-title":"Adv Neurol"},{"key":"169_CR44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","volume":"11","author":"J Jankovic","year":"1982","unstructured":"Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11:41\u20137.","journal-title":"Ann Neurol"},{"key":"169_CR45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archneur.1972.00490180039009","volume":"27","author":"GJ Gilbert","year":"1972","unstructured":"Gilbert GJ. The medical treatment of spasmodic torticollis. Arch Neurol. 1972;27:503\u20136.","journal-title":"Arch Neurol"},{"key":"169_CR46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1212\/WNL.27.2.198","volume":"27","author":"HH West","year":"1977","unstructured":"West HH. Treatment of spasmodic torticollis with amantadine: a double blind study. Neurology. 1977;27:198\u20139.","journal-title":"Neurology"},{"issue":"7765","key":"169_CR47","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(72)91137-3","volume":"1","author":"KM Shaw","year":"1972","unstructured":"Shaw KM, Hunter KR, Stren GM. Medical treatment of spasmodic Torticollis. Lancet. 1972;1(7765):1399.","journal-title":"Lancet"},{"key":"169_CR48","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.22.7.670","volume":"22","author":"KA Ansari","year":"1972","unstructured":"Ansari KA, Webster D, Manning N. Spasmodic torticollis and L-Dopa: results of therapeutic trial in six patients. Neurology. 1972;22:672\u20134.","journal-title":"Neurology"},{"key":"169_CR49","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/archneurpsyc.1942.02290110143009","volume":"48","author":"A Myerson","year":"1942","unstructured":"Myerson A, Loman J. Amphetamine sulfate in treatment of spasmodic torticollis. Arch Neurol Psychiatry. 1942;48:823\u20138.","journal-title":"Arch Neurol Psychiatry"},{"key":"169_CR50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/archneur.1979.00500430079017","volume":"36","author":"J Jantunen","year":"1979","unstructured":"Jantunen J, Kaste M, Iivanainen M, et al. Bromocriptine treatment of spasmodic torticollis: a double blind crossover study. Arch Neurol. 1979;36:449\u201350.","journal-title":"Arch Neurol"},{"issue":"5","key":"169_CR51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","volume":"14","author":"D Truong","year":"2008","unstructured":"Truong D, Comella C, Fernandez HH, Dysport Benign Essential Blepharospasm Study Group, et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14(5):407\u201314.","journal-title":"Parkinsonism Relat Disord."},{"issue":"8","key":"169_CR52","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","volume":"26","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Comella C, Hanschmann A, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011;26(8):1521\u20138.","journal-title":"Mov Disord"},{"issue":"2","key":"169_CR53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","volume":"118","author":"B Wabbels","year":"2011","unstructured":"Wabbels B, Reichel G, Fulford-Smith A, et al. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm. 2011;118(2):233\u20139.","journal-title":"J Neural Transm."},{"key":"169_CR54","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","volume":"37","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Orman J. Botulinum A toxin for cranial cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616\u201323.","journal-title":"Neurology"},{"key":"169_CR55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","volume":"235","author":"Z Nussgens","year":"1997","unstructured":"Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235:197\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"169_CR56","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","volume":"12","author":"C Sampaio","year":"1997","unstructured":"Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2014Dysport and Botox\u2014assuming a ratio of 4:1. Mov Disord. 1997;12:1013\u20138.","journal-title":"Mov Disord"},{"key":"169_CR57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenkamper","year":"2006","unstructured":"Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303\u201312.","journal-title":"J Neural Transm."},{"issue":"5","key":"169_CR58","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/IOP.0b013e3181b1e526","volume":"25","author":"DE Yomtoob","year":"2009","unstructured":"Yomtoob DE, Dewan MA, Lee MS, et al. Comparison of pain scores with 30-gauge and 32-gauge needles for periocular botulinum toxin type A injections. Ophthalmic Plast Reconstr Surg. 2009;25(5):376\u20137.","journal-title":"Ophthalmic Plast Reconstr Surg."},{"issue":"2","key":"169_CR59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/IOP.0b013e31819946c4","volume":"25","author":"MH Boyle","year":"2009","unstructured":"Boyle MH, McGwin Jr G, Flanagan CE, et al. High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference? Ophthalmic Plast Reconstr Surg. 2009;25(2):81\u20134.","journal-title":"Ophthalmic Plast Reconstr Surg."},{"issue":"4","key":"169_CR60","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/mds.23549","volume":"26","author":"R Reese","year":"2011","unstructured":"Reese R, Gruber D, Schoenecker T, et al. Long-term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation. Mov Disord. 2011;26(4):691\u20138.","journal-title":"Mov Disord"},{"key":"169_CR61","first-page":"429","volume-title":"Therapy with Botulinum Toxin","author":"MF Brin","year":"1994","unstructured":"Brin MF. Oromandibular dystonia: treatment of 96 patients with botulinum toxin type A. In: Jankovic J, Hallett M, editors. Therapy with Botulinum Toxin. New York: Marcel Dekker; 1994. p. 429\u201335."},{"key":"169_CR62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/000348948909800202","volume":"98","author":"A Blitzer","year":"1989","unstructured":"Blitzer A, Brin MF, Greene PE, et al. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol. 1989;98:93\u20137.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"169_CR63","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1288\/00005537-199111000-00010","volume":"101","author":"N Hermanowicz","year":"1991","unstructured":"Hermanowicz N, Truong DD. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope. 1991;101:1216\u20138.","journal-title":"Laryngoscope"},{"key":"169_CR64","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.880180708","volume":"18","author":"P Bergh Van den","year":"1995","unstructured":"Van den Bergh P, Francart J, Mourin S, et al. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve. 1995;18:720\u20139.","journal-title":"Muscle Nerve"},{"key":"169_CR65","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","volume":"37","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616\u201323.","journal-title":"Neurology"},{"key":"169_CR66","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1212\/WNL.53.9.2102","volume":"53","author":"EK Tan","year":"1999","unstructured":"Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53:2102\u20137.","journal-title":"Neurology"},{"issue":"1","key":"169_CR67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-1331.2006.01441.x","volume":"13","author":"R Bhidayasiri","year":"2006","unstructured":"Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol. 2006;13(1):21\u20139.","journal-title":"Eur J Neurol"},{"issue":"5","key":"169_CR68","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.toxicon.2008.12.008","volume":"54","author":"M Hallett","year":"2009","unstructured":"Hallett M, Benecke R, Blitzer A, et al. Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009;54(5):628\u201333.","journal-title":"Toxicon"},{"key":"169_CR69","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mds.870030107","volume":"3","author":"P Greene","year":"1988","unstructured":"Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord. 1988;3:46\u201360.","journal-title":"Mov Disord"},{"key":"169_CR70","first-page":"443","volume":"49","author":"HL Klawans","year":"1988","unstructured":"Klawans HL, Tanner CM. Cholinergic pharmacology of blepharospasm with oromandibular dystonia (Meige\u2019s syndrome). Adv Neurol. 1988;49:443\u201350.","journal-title":"Adv Neurol"},{"issue":"3","key":"169_CR71","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1523\/JNEUROSCI.2758-10.2011","volume":"31","author":"CL Ludlow","year":"2011","unstructured":"Ludlow CL. Spasmodic dysphonia: a laryngeal control disorder specific to speech. J Neurosci. 2011;31(3):793\u20137.","journal-title":"J Neurosci"},{"key":"169_CR72","doi-asserted-by":"crossref","unstructured":"Watts CC, Whurr R, Nye C. Botulinum toxin injections for the treatment of spasmodic dysphonia. Cochrane Database Syst Rev. 2004:CD004327.","DOI":"10.1002\/14651858.CD004327.pub2"},{"issue":"2","key":"169_CR73","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1191\/0269215506cr931oa","volume":"20","author":"CR Watts","year":"2006","unstructured":"Watts CR, Nye C, Whurr R. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review. Clin Rehabil. 2006;20(2):112\u201322.","journal-title":"Clin Rehabil"},{"issue":"3","key":"169_CR74","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1044\/1092-4388(2002\/037)","volume":"45","author":"F Boutsen","year":"2002","unstructured":"Boutsen F, Cannito MP, Taylor M, et al. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res. 2002;45(3):469\u201381.","journal-title":"J Speech Lang Hear Res."},{"key":"169_CR75","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/13682829809179445","volume":"33","author":"R Whurr","year":"1998","unstructured":"Whurr R, Nye C, Lorch M. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. Int J Lang Commun Disord. 1998;33:327\u20139.","journal-title":"Int J Lang Commun Disord."},{"key":"169_CR76","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1288\/00005537-199106000-00010","volume":"101","author":"DD Troung","year":"1991","unstructured":"Troung DD, Rontal M, Rolnick M, et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope. 1991;101:630\u20134.","journal-title":"Laryngoscope"},{"key":"169_CR77","first-page":"209","volume":"24","author":"DL Wong","year":"1995","unstructured":"Wong DL, Adams SG, Irish JC, et al. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia. J Otolaryngol. 1995;24:209\u201316.","journal-title":"J Otolaryngol"},{"key":"169_CR78","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/000348940111000503","volume":"110","author":"S Bielamowicz","year":"2001","unstructured":"Bielamowicz S, Squire S, Bidus K, et al. Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol. 2001;110:406\u201312.","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"6","key":"169_CR79","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/000348940311200603","volume":"112","author":"L Sulica","year":"2003","unstructured":"Sulica L, Blitzer A, Brin MF, et al. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section. Ann Otol Rhinol Laryngol. 2003;112(6):499\u2013505.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"169_CR80","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp.2005.083170","volume":"78","author":"JJ Kruisdijk","year":"2007","unstructured":"Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al. Botulinum toxin for writer\u2019s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007;78:264\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"169_CR81","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.42.3.627","volume":"42","author":"DM Yoshimura","year":"1992","unstructured":"Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology. 1992;42:627\u201330.","journal-title":"Neurology"},{"key":"169_CR82","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.43.1_Part_1.183","volume":"43","author":"JK Tsui","year":"1993","unstructured":"Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer\u2019s cramp: a double-blind study. Neurology. 1993;43:183\u20135.","journal-title":"Neurology"},{"key":"169_CR83","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mds.870100411","volume":"10","author":"R Cole","year":"1995","unstructured":"Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord. 1995;10:466\u201371.","journal-title":"Mov Disord"},{"key":"169_CR84","first-page":"923","volume":"159","author":"MH Marion","year":"2003","unstructured":"Marion MH, Afors K, Sheehy MP. Problems of treating writer\u2019s cramp with botulinum toxin injections: results from 10 years of experience. Rev Neurol (Paris). 2003;159:923\u20137.","journal-title":"Rev Neurol (Paris)"},{"key":"169_CR85","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.58.5.805","volume":"58","author":"FM Molloy","year":"2002","unstructured":"Molloy FM, Shill HA, Kaelin-Lang A, et al. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology. 2002;58:805\u20137.","journal-title":"Neurology"},{"key":"169_CR86","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1017\/S0317167100038506","volume":"23","author":"C Geenen","year":"1996","unstructured":"Geenen C, Consky E, Ashby P. Localizing muscles for botulinum toxin treatment of focal hand dystonia. Can J Neurol Sci. 1996;23:194\u20137.","journal-title":"Can J Neurol Sci"},{"key":"169_CR87","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/1531-8257(199903)14:2<307::AID-MDS1016>3.0.CO;2-3","volume":"14","author":"R Chen","year":"1999","unstructured":"Chen R, Karp BI, Goldstein SR, et al. Effect of muscle activity immediately after botulinum toxin injection for writer\u2019s cramp. Mov Disord. 1999;14:307\u201312.","journal-title":"Mov Disord"},{"issue":"5","key":"169_CR88","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3171\/JNS-07\/11\/0977","volume":"107","author":"C Fukaya","year":"2007","unstructured":"Fukaya C, Katayama Y, Kano T, et al. Thalamic deep brain stimulation for writer\u2019s cramp. J Neurosurg. 2007;107(5):977\u201382.","journal-title":"J Neurosurg"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0169-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-012-0169-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0169-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T10:16:19Z","timestamp":1713694579000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-012-0169-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,14]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["169"],"URL":"https:\/\/doi.org\/10.1007\/s11940-012-0169-6","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,14]]}}}